Literature DB >> 22160036

Genetic and epigenetic complexity in myeloproliferative neoplasms.

Nicholas C P Cross1.   

Abstract

The past 7 years have witnessed remarkable progress in our understanding of the genetics of BCR-ABL-negative myeloproliferative neoplasms (MPNs) and has revealed layers of unexpected complexity. Deregulation of JAK2 signaling has emerged as a central feature, but despite having biological activities that recapitulate the cardinal features MPNs in model systems, JAK2 mutations are often secondary events. Several other mutated genes have been identified with a common theme of involvement in the epigenetic control of gene expression. Remarkably, the somatic mutations identified to date do not seem to be acquired in any preferred order, and it is possible that the disease-initiating events remain to be identified. The finding of complex clonal hierarchies in many cases suggests genetic instability that, in principle, may be inherited or acquired. A common haplotype has been identified that is strongly associated with the acquisition of JAK2 mutations, but the cause of relatively high-penetrance familial predisposition to MPNs remains elusive. This review summarizes the established facts relating to the genetics of MPNs, but highlights recent findings and areas of controversy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160036     DOI: 10.1182/asheducation-2011.1.208

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  38 in total

1.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

2.  Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

Authors:  Ana Paula Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Biomed Rep       Date:  2017-09-05

3.  SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA.

Authors:  Subbaiah Chary Nimmagadda; Stephanie Frey; Peter Müller; Denise Wolleschak; Sönke Weinert; Ulrich Keller; Bärbel Edelmann; Thomas Fischer
Journal:  Haematologica       Date:  2019-02-14       Impact factor: 9.941

4.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

5.  Myeloproliferative neoplasms.

Authors:  Amy Publicover; Patrick Medd
Journal:  Clin Med (Lond)       Date:  2013-04       Impact factor: 2.659

6.  Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report.

Authors:  Gyeongmin Jeong; Jinhyong Kim; Seeun Han; Jongmin Lee; Kyunghye Park; Chuiyong Pak; Ji-Hun Lim; Hee Jeong Cha; Hawk Kim; Jae-Cheol Jo
Journal:  Oncol Lett       Date:  2015-12-21       Impact factor: 2.967

7.  Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Authors:  Ruben A Mesa; Srdan Verstovsek; Vikas Gupta; John O Mascarenhas; Ehab Atallah; Timothy Burn; William Sun; Victor Sandor; Jason Gotlib
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-27

Review 8.  Ruxolitinib dose management as a key to long-term treatment success.

Authors:  Ruben A Mesa; Rami S Komrokji; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-08-27       Impact factor: 2.490

Review 9.  Ruxolitinib for myelofibrosis--an update of its clinical effects.

Authors:  Hagop M Kantarjian; Richard T Silver; Rami S Komrokji; Ruben A Mesa; Roland Tacke; Claire N Harrison
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-02

10.  SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Authors:  Maya Koren-Michowitz; Sigal Gery; Takayuki Tabayashi; Dechen Lin; Rocio Alvarez; Arnon Nagler; H Phillip Koeffler
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.